Zhuhai Gene-Biocon

Zhuhai Gene-Biocon Biological Technology Co., Ltd. is a Chinese biotechnology company founded in 2015 that specializes in synthetic biology and recombinant protein production. The company focuses on developing high-activity biological raw materials and biosimilar pharmaceuticals, particularly targeting metabolic disorders such as diabetes and obesity. Its core product line includes biosimilars for Insulin Degludec, Insulin Aspart, Liraglutide, and Semaglutide, alongside a variety of recombinant enzymes and growth factors. Gene-Biocon operates a GMP-certified manufacturing facility in Zhuhai, providing CDMO, ODM, and OEM services to the global life sciences and cosmetic industries. The company's lead candidate, an Insulin Degludec biosimilar, has received IND approval from China's National Medical Products Administration (NMPA).